Abstract:BACKGROUND Complex assessment of the development, clinical and immunological state of children born by mothers with type 1 diabetes, in the years 1998-2000. MATERIALS AND METHODS Material examined were 30 newborns, and subsequently 25 in the first, 30 children at 5-6 years of life. In newborns and in the 5-6 years the antibodies: IA-2A, IAA, ICA, anti GAD, insulin (IRI), peptide C were determined. In the first year HbA(1c), TSH, antigens HLA DQA1 and DQB1 were determined, in the 5th-6th years of life, the level of antibodies anti endomizium. RESULTS Developmental anomalies in newborns were found in 6, in 3 in first and in the 5th-6th years in 4 children. Systemic infections were found in 6, hypoxia and prematurity in 12 newborns. A positive titer of anti GAD in 15, ICA in 18, IA-2A in 8, IAA in 18 newborns. In the first year of life, anti GAD in 2, in the 5-6th years in 4 children. In one child anti GAD was found during three examinations. In the case of this positive titer of antibodies, the allele DQB1*0302 was present. Allel DQB1*0302 was present in 28% of children, allele DQA1*0301 was absent. Mean levels of IRI afterbirth and in the first year of life were: 23.6 and 9.7 uIU/ml and peptide C 1.25 and 0.92 ng/ml. Mean levels of HbA(1c) in the first and 5th yrs of life were: x 6.2%, TSH 2.45 uIU/ml and 3.4 uIU/ml. Pathological values of antibodies anti endomizium were found in 4 children, biopsy of the small intestine confirmed coeliac disease. A normal body mass was seen in 9 newborns in 16 in the first, and 14 children 5-6 years of age. Deficiency in body mass was found in 2 newborns and 3 children in the first and 5-6th yrs. Macrosomia was found in 8 newborns in group I and 3 in group II. Overweight was found in 5 children in the first year and 9 in 5-6th yrs of life. None of the children have developed diabetes. CONCLUSIONS 1. Children of mothers with type 1 diabetes should be monitored by an outpatient clinic for diabetic patients. 2. Children of mothers with diabetes should have determined regularly immunological markers for diabetes and other autoimmunological disease.

Research and application of zirconia dental ceramics

Advances and challenges in zirconia-based materials for dental applications

Zirconia ceramics in metal-free implant dentistry

Advances in Zirconia-Based Dental Materials: Properties, Classification, Applications, and Future Prospects

A review on surface texturing of zirconia ceramics for dental applications

Clinical application principles and new developments of zirconia crown

Zirconia as a Dental Biomaterial

Zirconia in biomedical applications

Research Progress on All Ceramic Zirconia Core/Veneer Interface: A Review

Zirconia Based Dental Biomaterials: Structure, Mechanical Properties, Biocompatibility, Surface Modification, and Applications as Implant

Novel Zirconia Materials in Dentistry

Advances in ceramics for tooth repair: From bench to chairside

Additive Manufacturing of Zirconia Ceramic and Its Application in Clinical Dentistry: A Review

Nanostructured Zirconia-Based Ceramics and Composites in Dentistry: A State-of-the-Art Review

Zirconia Materials for Dental Implants: A Literature Review

Preparation and Properties of Dental Zirconia Ceramics

An overview of zirconia ceramics: Basic properties and clinical applications

Domestic Clinical Application and Research Development of Dental Machinable Ceramics Materials

Recent progress in additive manufacturing of ceramic dental restorations

[Complex analysis of the physical metabolic and genetic state in children of mothers with type 1 diabetes].